SCS01: Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice-Best Practices and Emerging Evidence in Limited Stage SCL

Pdf Summary

The document discusses best practices and emerging evidence in the treatment of Limited Stage Small Cell Lung Cancer (LS-SCLC), focusing on the role of local therapy and radiotherapy. Percy Lee, M.D., provides an overview of various studies and trials including Pignon's NEJM 1992, Intergroup 0096, CONVERT, CALGB 30610/RTOG 0538, and others that assess the efficacy of different radiotherapy doses and schedules in LS-SCLC and their impact on overall survival (OS) and progression-free survival (PFS).<br /><br />In LS-SCLC, early stage treatment often involves surgical interventions like lobectomy with adjuvant chemotherapy, or radiation therapy for medically inoperable cases. The CONVERT trial concluded no significant survival difference between twice-daily (BID) and once-daily (QD) radiotherapy schedules, although BID is suggested as a standard due to its consistent results across various studies.<br /><br />Another trial, CALGB 30610/RTOG 0538, compared different radiotherapy regimens, showing similar OS and toxicity rates for BID and QD schedules. The Grønberg study, focusing on hyperfractionated thoracic radiotherapy, highlighted better survival with 60 Gy BID compared to 45 Gy BID.<br /><br />The role of immunotherapy is also being explored in ongoing trials like NRG LU005 and the ADRIATIC Trial, assessing the combination with or following chemoradiotherapy to enhance treatment efficacy. Prophylactic cranial irradiation (PCI) is reviewed as a preventative measure against brain metastasis.<br /><br />The findings underscore the importance of continual clinical trials and research to refine treatment protocols in LS-SCLC, integrating advances in immunotherapies and personalized medicine to improve patient outcomes.

Asset Subtitle

Percy Lee

Keywords

Limited Stage Small Cell Lung Cancer

LS-SCLC

radiotherapy

local therapy

clinical trials

immunotherapy

Prophylactic Cranial Irradiation

CONVERT trial

CALGB 30610/RTOG 0538

survival outcomes